Anti-EGR2 antibody produced in mouse

Early growth response 2 (EGR2) is a zinc finger transcription factor and a member of the EGR family. Structurally, it comprises activation domain(A), DNA binding domain (DBD) zinc finger domain, basic domain (BD) and broadly neutralizing antibody (BNab) interaction domain(R1). The EGR2 gene is mapped to human chromosome 10q21.3.

EGR2 (NP_000390.2, 1 a.a. ~ 476 a.a) full-length human protein.

Sequence
MMTAKAVDKIPVTLSGFVHQLSDNIYPVEDLAATSVTIFPNAELGGPFDQMNGVAGDGMINIDMTGEKRSLDLPYPSSFAPVSAPRNQTFTYMGKFSIDPQYPGASCYPEGIINIVSAGILQGVTSPASTTASSSVTSASPNPLATGPLGVCTMSQTQPDLDHLYSPPPPPPPYSGCAGDLYQDPSAFLSAATTSTSSSLAYPPPPSYPSPKPATDPGLFPMIPDYPGFFPSQCQRDLHGTAGPDRKPFPCPLDTLRVPPPLTPLSTIRNFTLGGPSAGVTGPGASGGSEGPRLPGSSSAAAAAAAAAAYNPHHLPLRPILRPRKYPNRPSKTPVHERPYPCPAEGCDRRFSRSDELTRHIRIHTGHKPFQCRICMRNFSRSDHLTTHIRTHTGEKPFACDYCGRKFARSDERKRHTKIHLRQKERKSSAPSASVPAPSTASCSGGVQPGGTLCSSNSSSLGGGPLAPCSSRTRTP

Early growth response 2 (EGR2) is essential for peripheral nerve myelination and T cell anergy. It is also needed for the formation of gap junction beta 1 (GJB1) and periaxin along with other myelin proteins. Mutations in the EGR2 gene are implicated in peripheral neuropathies namely Charcot-Marie-Tooth disease type 1 (CMT1), congenital hypomyelinating neuropathy (CHN), and Dejerine-Sottas neuropathy (DSN/CMT). EGR2 upregulation may regulate inflammatory cytokines during recovery from Guillain-Barré syndrome (GBS).

Solution in phosphate buffered saline, pH 7.4

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.